HOLBROOK, N.Y., March 21, 2013 /PRNewswire/ -- Northstar Global Business Services, Inc. Symbol (OTCPink: MDIN), today announced it has already started manufacturing product for a massive push into Europe with its popular anti-snoring product, Snorenz. Once Snorenz is being sold across Europe, the company has plans to follow it with its other product lines shortly thereafter. Manufacturing is already underway, and the company will be prepared to ship approximately one million units starting August 1st to supply the initial non-US orders of the product.

The company CEO, Nick Chieco commented, "Obviously we are thrilled to have put this together and working to coordinate with several distributors and overseas manufacturers was challenging but rewarding." He went on to say, "I know our shareholders and customers are anxious not only to see our products on the shelves of retail stores near them, but to see the exact sales numbers resulting from all of our hard work. Although these transactions are extremely complex and take some time, we are coming closer and closer to being able to deliver those two things. When our current quarter's financials come out, I think everyone will be impressed with our revenues and profit margins."

Outside the US, the retail price of a 2 ounce bottle of Snorenz will be slightly higher, at about the equivalent of $14.00 USD, but the net profit to Northstar will be about the same, and the company's research shows that due to lack of competing products and current interest, the European market should bear the price nicely. The company wants it known that the Northstar is prepared to make its mark in the alternative heathcare industry, not only nationally, but globally.

For more information about Northstar, Contact Jennifer at 1-877-571-4387 or Email: investors@northstarbb.com

About Northstar
Northstar Global Business Services is dedicated to producing the best alternative healthcare products. The most popular products in Northstar's arsenal are Snorenz©, a patented spray for snoring relief and "Good Night's Sleep", an FDA approved sleep aid. Most of the company's products use a unique spray delivery system, and have received very positive consumer reviews all over the world, selling millions upon millions of units from 1996 to the present.

DISCLAIMER
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

SOURCE Northstar Global Business Services, Inc.

Copyright 2013 PR Newswire

MedGen (CE) (USOTC:MDIN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos MedGen (CE).
MedGen (CE) (USOTC:MDIN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos MedGen (CE).